Renzenbrink & Partner advises on the sale of TeleClinic GmbH to Zur Rose Group AG

17 July 2020

The Swiss Zur Rose Group AG has acquired TeleClinic GmbH, headquartered in Munich, for a purchase price in the mid-double-digit million Euro range. The fast-growing tech start-up, founded in 2015 by Katharina Jünger, has rapidly achieved the status of the leading telemedicine provider in Germany and is considered a pioneer of on-demand telemedicine services including digital prescriptions and sick-notes. TeleClinic is expected to expand its market position as the penetration of digital health services will continue to rise in a post COVID-19 world.

The Swiss Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. The company is internationally present with strong brands, including Germany’s best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people in Europe and generated in 2019 revenues of more than 1.5 billion Swiss Francs and has around nine million active customers in European core markets.

Renzenbrink & Partner has already advised TeleClinic on the last financing round in 2018 and is now also engaged with the legal advice on the exit transaction which included all legal- and tax-related aspects of the sale. The team of Renzenbrink & Partner comprises the partners Dr Dennis Schlottmann (Corporate/M&A) and Marc H. Kotyrba (Tax) as well as the associate Dr Alexander Haunschild (Corporate/M&A).